Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival

Prior clinical trials largely considered prednisone 1 mg/kg per day with or without calcineurin inhibitor as standard initial therapy for chronic graft-versus-host disease (cGVHD), but uncertainty remains regarding the extent of practice variation and whether this affects subsequent outcomes. We ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Pidala, Joseph, Onstad, Lynn, Martin, Paul J., Hamilton, Betty K., Cutler, Corey, Kitko, Carrie L., Carpenter, Paul A., Chen, George L., Arora, Mukta, Flowers, Mary E. D., Arai, Sally, Alousi, Amin, White, Jennifer, Jacobsohn, David, Pusic, Iskra, Lee, Stephanie J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759136/
https://www.ncbi.nlm.nih.gov/pubmed/34535015
http://dx.doi.org/10.1182/bloodadvances.2021005286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759136/
https://www.ncbi.nlm.nih.gov/pubmed/34535015
http://dx.doi.org/10.1182/bloodadvances.2021005286

Ejemplares similares